What Merck's FY2025 10-K says: 9 signals
Merck filed its latest 10-K with the SEC on Feb 24, 2026. It discusses acquisition announced, automation investment and capacity constraint.
Get Merck's live signals in Claude or ChatGPT, or by API
What changed at Merck this week? Use Autobound signals for merck.com.- Filed
- Feb 24, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
Source: Autobound Signal API · 92 signals tracked for Merck · updated
10-K · latest 9
What Merck's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 9 signals
Company anticipates future litigation over Keytruda patents to defend market exclusivity.
Merck expects legal challenges over two ancillary patents for Keytruda that expire in 2029.
Adopting adaptive Phase 2/3 trial designs to accelerate drug development timelines.
Merck is using adaptive clinical trial designs to shorten the time-to-market for new drugs by combining study phases.
adaptive design methodology
A significant portion of Merck's Phase 3 drug candidates are being co-developed with external partners.
AstraZenecaBayer AGEisai Co., Ltd.
Received expedited FDA review vouchers for two Phase 3 drug candidates in Dec 2025.
Receiving Commissioner’s National Priority Vouchers for enlicitide decanoate and sacituzumab tirumotecan will significantly accelerate their potential approval.
Commits to acquisitions and licensing as a key pipeline strategy to supplement internal R&D.
To combat upcoming patent expirations, Merck is actively pursuing externally sourced programs through acquisitions and licensing.
Dependent on collaborations with AstraZeneca, Eisai, and Bayer for key products.
Merck's portfolio includes major products like Lynparza, Lenvima, and Adempas, which are commercialized through strategic collaborations.
Eisai Co., Ltd.AstraZenecaBayer AG
Merck signals M&A and licensing focus to supplement internal R&D pipeline.
Facing the major Keytruda patent expiration in 2028, Merck is explicitly committed to using acquisitions and external alliances to bolster its drug pipeline.
Merck partners with Eisai Co., Ltd. on strategic oncology drug Lenvima.
Merck's collaboration with Eisai is crucial for its oncology franchise, a key growth area for the company.
Eisai Co., Ltd.
Merck is advancing a large Phase 3 pipeline with over 15 candidates.
Merck is heavily investing in its late-stage pipeline, including candidates like V940, ifinatamab deruxtecan, and enlicitide decanoate, to secure future revenue streams.
Signal API · MCP
Track Merck with the Signal API
One POST /v1/companies/enrich call with merck.com returns Merck 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"merck.com","signal_types":["sec-10k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-K Filings records, as a CSV.
Same industry
10-K at related companies
Questions about Merck 10-K
When did Merck file its latest 10-K?
What does Merck's latest 10-K say about litigation material?
Where can I find Merck's annual report?
Page updated , the date of the newest row on this page.
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .